IDEV Technologies has launched Supera Veritas Peripheral Vascular System, a novel stent delivery system in Europe. The system was formally launched in the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010 conference in Leipzig, Germany.
The Supera Veritas system was developed by IDEV to deliver its self-expanding Supera interwoven nitinol stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD). The company expects to introduce two additional products in its family of Supera stents by the end of this year.
The Supera Interwoven Self-Expanding Nitinol Stent Transhepatic Biliary system has received 510(k) clearance for palliative treatment for biliary strictures produced by malignant neoplasms. The system has received CE mark approval in Europe for biliary and peripheral vascular indications.
Christopher Owens, CEO of IDEV, said: “The early clinical results using our novel stent delivery system have been impressive and have demonstrated IDEV’s capacity for innovation. Physician feedback on the new Supera Veritas delivery system indicates that we have provided the operator with a product that has improved durability, reliability, accuracy and ease of use.
“These results have triggered significant interest in our stent. We have been very pleased with the early acceptance of our new Supera Veritas delivery system since introducing it to a European audience at LINC 2010.
“We recorded a year-over-year revenue growth rate of nearly 70% in the first quarter of this year, and we anticipate an increasing rate of adoption and sizeable increases in market share as the launch of our new delivery system gains even greater traction in the market.”